Cited by 1,568Cannabis and Cannabinoid ResearchReceptor Mechanisms and SignalingNeuroscience and Neuropharmacology Research

The orphan receptor GPR55 is a novel cannabinoid receptor

Open access
Ryberg, E, Larsson, N, Sjögren, S, Hjorth, S, Hermansson, N‐O, Leonova, J, Elebring, T, Nilsson, K +2 more·2007·British Journal of Pharmacology

Abstract

BACKGROUND: The endocannabinoid system functions through two well characterized receptor systems, the CB1 and CB2 receptors. Work by a number of groups in recent years has provided evidence that the system is more complicated and additional receptor types should exist to explain ligand activity in a number of physiological processes. EXPERIMENTAL APPROACH: Cells transfected with the human cDNA for GPR55 were tested for their ability to bind and to mediate GTPgammaS binding by cannabinoid ligands. Using an antibody and peptide blocking approach, the nature of the G-protein coupling was determined and further demonstrated by measuring activity of downstream signalling pathways. KEY RESULTS: We demonstrate that GPR55 binds to and is activated by the cannabinoid ligand CP55940. In addition endocannabinoids including anandamide and virodhamine activate GTPgammaS binding via GPR55 with nM potencies. Ligands such as cannabidiol and abnormal cannabidiol which exhibit no CB1 or CB2 activity and are believed to function at a novel cannabinoid receptor, also showed activity at GPR55. GPR55 couples to Galpha13 and can mediate activation of rhoA, cdc42 and rac1. CONCLUSIONS: These data suggest that GPR55 is a novel cannabinoid receptor, and its ligand profile with respect to CB1 and CB2 described here will permit delineation of its physiological function(s).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0707460

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AEA actions are not restricted to CB1R; ECBs also act at CB2R, GPR55, TRPV1, and other G protein subtypes such as Gs and/or Gq11.

    “Enriching the picture further, the actions of AEA are not restricted to CB1R, given that ECBs also act, sometimes in a non-retrograde manner, at CB2R [30], GPR55 [31], and TRPV1 (transient receptor potential vanilloid type 1) channels [32–34], as well as other G protein subtypes such as Gs and/or Gq11 [35,36].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J.
Affiliations
AstraZeneca (Sweden) (SE)
Corresponding author
Greasley, P J
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2007-12
Volume
152
Issue
7
Pages
1092-1101
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1819429514
Cited by
1,568
References
49
Citations by year
2026: 36 · 2025: 65 · 2024: 70 · 2023: 79 · 2022: 112 · 2021: 126 · 2020: 123 · 2019: 96 · 2018: 91 · 2017: 82 · 2016: 76 · 2015: 71 · 2014: 76 · 2013: 71 · 2012: 77
FWCI
52.95
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
GPR55, orphan receptors, cannabinoid receptors, endocannabinoid system, CP55,940, anandamide, cannabidiol, Gα13, G protein coupling, RhoA, Cdc42, Rac1, receptor signaling
MeSH terms
Amino Acid Sequence, Animals, Arachidonic Acids, Binding Sites, Binding, Competitive, Cannabidiol, Cannabinoids, Cell Line, Cloning, Molecular, Cyclohexanols, Humans, Ligands, Molecular Sequence Data, Organ Specificity, RNA, Messenger, Structure-Activity Relationship, Signal Transduction, Down-Regulation, Polymerase Chain Reaction, Guanosine 5'-O-(3-Thiotriphosphate), Receptors, G-Protein-Coupled, Receptors, Cannabinoid, Mice, Rats, Polyunsaturated Alkamides, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review